Melissa Jones
Program Manager, Metabolic Disorders FNIH
Seminars
Wednesday 15th April 2026
Powering Adaptive GLP-1 Trial Designs using Qualifying Biomarkers for Accelerated Dose Selection and Multi-Indication Insight
5:30 pm
- Accelerating dose optimization by leveraging FNIH-validated non-invasive biomarkers (e.g., in MASH) as reliable, rapid surrogate endpoints in seamless adaptive trial models
- Defining the full therapeutic value of GLP-1s by prioritizing the early standardization and integration of multi-indication endpoints, such as muscle preservation and heart failure (HF) risk markers
- Harmonizing biomarker protocols across clinical trials and Real-World Data (RWD) to enhance patient retention and ensure robust, consistent long-term safety and efficacy analysis
